secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2025-12-02T23:59:59+00:00
Accession:  0001193125-25-304486
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health reports positive 6-month REVEAL-1 data for Revita in post-GLP-1 weight maintenance
--------------------------------------------------------------------------------

- Participants who lost ~24% body weight on GLP-1 drugs had mean 1.5% weight change at 6 months after Revita (n=17), vs ~10% regain in literature.
- HbA1c change was 0.04% after Revita vs ~0.4% increase in STEP-1 extension; no procedure-related serious adverse events.
- Upcoming catalysts: Jan 2026 REMAIN-1 6-month randomized data; H2 2026 pivotal topline data and potential PMA filing.
- Revita received FDA Breakthrough Device designation for post-GLP-1 weight maintenance.
- Average ablation length ~16 cm, consistent with prior experience, supporting scalability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000119312525304486/0001193125-25-304486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000119312525304486/guts-20251202.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-304486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer